Wednesday, October 14, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 22, 2026

What Is Really Destroying Social Security and What Congress Could Actually Do to Fix It

View original at finance.yahoo.com
What Is Really Destroying Social Security and What Congress Could Actually Do to Fix It Quick Read Social Security’s $2.5 trillion trust fund is invested in special-issue government bonds as required by law; the real crisis is demographic—fewer workers supporting more retirees as baby boomers retire, with the combined…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Social Security is not going broke because politicians raided the piggy bank; the trust fund's $2.5 trillion in reserves is properly invested in special-issue government bonds, exactly as the law requires

    60% confidence

  • High earners stop contributing once their wages cross the threshold, which is why lifting the cap is a perennial reform proposal

    60% confidence

  • The real problem is slower and harder to fix: the math of an aging country is quietly grinding the program toward a cliff

    60% confidence

  • The combined trust fund depletes in 2034, leaving incoming revenue to cover only 81% of scheduled benefits

    60% confidence

Data points we hold from this source

Social Security Administration · benefit coverage after depletion81 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
What Is Really Destroying Social Security and What Congress Could Actually Do to Fix It — Source | Via News | Via News